Chemed Corporation filings document a Delaware operating company whose capital stock trades on the NYSE under CHE and whose business is conducted through VITAS Healthcare and Roto-Rooter. Current reports disclose segment operating results for hospice and palliative care services, plumbing and drain cleaning services, patient-care metrics, service revenue and capital allocation.
Chemed's regulatory record also includes 8-K disclosures for earnings releases, Regulation FD updates, senior secured revolving credit facilities and related direct financial obligations. Proxy materials cover director elections, executive compensation, pay-versus-performance data and governance matters, while event reports record leadership changes within the VITAS business.
Chemed Corp (CHE) president and CEO Kevin J. McNamara sold 2,000 shares of capital stock on November 3, 2026, at a weighted-average price of $537.90 per share. The shares were sold in multiple transactions at prices ranging from $532.34 to $546.52. He directly held 82,220 shares after the sale. The reported share count was increased by 19,802 shares to correct an administrative error in the July 31, 2026 filing and include shares omitted from an option conversion calculation. No Rule 10b5-1 plan is reported.
Chemed Corporation (CHE) lists a proposed sale for the account of officer/director Kevin J McNamara of 2,000 common shares, with an aggregate market value of $1,084,360 and an approximate sale date of November 3, 2026. Merrill Lynch is listed as broker. The notice also lists prior sales by McNamara of 2,000 shares each on August 21, September 17 and September 28, 2026.
Chemed Corp executive vice president Spencer S. Lee sold 920 shares of Capital Stock on November 2, 2026, at a weighted average price of $537.17 per share. The shares were sold in multiple transactions at prices ranging from $536.26 to $537.70. Lee directly held 13,931 shares after the sale. No Rule 10b5-1 plan is reported for the sale.
Chemed Corporation (CHE) reported third-quarter 2026 service revenues and sales of $690.9 million, versus $624.9 million in 2025, and net income of $71.6 million, versus $64.2 million. Diluted earnings per share were $5.45, compared with $4.46. VITAS generated $457.4 million in third-quarter revenue and Roto-Rooter $233.5 million; their year-earlier revenue was $407.7 million and $217.2 million, respectively.
During the first nine months, service revenues and sales were $2,021.7 million versus $1,890.6 million, and net income was $205.7 million versus $188.5 million. Net cash provided by operating activities was $229.6 million, compared with $254.7 million in 2025. Cash used in investing activities was $147.4 million, including $96.1 million for business combinations and $51.4 million in capital expenditures. Cash purchases of treasury stock were $350.0 million. As of September 30, 2026, long-term debt was $236.0 million and cash and equivalents were $48.4 million.
Chemed Corporation (CHE) reported third-quarter 2026 revenue of $690.9 million and net income of $71.6 million, versus $624.9 million and $64.2 million a year earlier. Diluted EPS was $5.45, compared with $4.46; adjusted diluted EPS was $6.75 versus $5.27. VITAS revenue rose 12.2% to $457.4 million, and adjusted EBITDA excluding Medicare Cap was $92.5 million, up 31.4%. Roto-Rooter revenue rose 7.5% to $233.5 million, while adjusted EBITDA declined 2.5% to $48.2 million.
Roto-Rooter re-acquired multiple California franchise territories for approximately $62.5 million; collectively, they cover a population of over 12 million. Slightly over half of their associated revenue will become part of owned and operated branches. Chemed repurchased 125,000 shares for $66.0 million in the quarter. For the nine months ended September 30, 2026, net cash provided by operating activities was $229.6 million, compared with $254.7 million in the same 2025 period. At September 30, 2026, cash was $48.4 million and long-term debt was $236.0 million. Management estimated full-year 2026 adjusted EPS would be at or slightly above the high-end of its guidance.
Chemed Corp. (CHE) reported a stock-option award to Joel L. Wherley, identified as CEO - Vitas Healthcare, covering 12,686 shares on October 20, 2026. The options have an exercise price of $512.64 per share and vest in three equal annual installments beginning October 20, 2027. Wherley's reported resulting option position was 42,906 underlying shares.
Chemed Corp. executive vice president Spencer S. Lee acquired 7,125 stock options on October 20, 2026, with an exercise price of $512.64 per share and an expiration date of October 20, 2031. His reported direct option position after the grant was 23,222 options.
Chemed Corp. (CHE) reported that Brian C. Judkins, VP and Chief Legal Officer, acquired a grant of 9,392 stock options on October 20, 2026, at an exercise price of $512.64 per share. His reported direct option position following the grant was 40,673 shares. The options expire October 20, 2031.
CHEMED CORP (CHE) reported that vice president and director Thomas C. Hutton received a direct award of options covering 3,964 shares on October 20, 2026. The options have an exercise price of $512.64 per share, vest in three equal annual installments beginning October 20, 2027, and expire October 20, 2031. Hutton’s reported direct option position after the award covered 26,053 shares.
Chemed Corp. VP & Chief Financial Officer Michael D. Witzeman received an award of stock options covering 12,686 shares on October 20, 2026, at an exercise price of $512.6400 per share. The options vest in three equal annual installments commencing October 20, 2027, and expire October 20, 2031. The reported post-award position was options covering 66,656 shares.